Universität zu Köln

Erger, Florian ORCID: 0000-0002-2768-1702 and Beck, Bodo B. (2021). A new era of treatment for primary hyperoxaluria type 1. Nat. Rev. Nephrol., 17 (9). S. 573 - 575. BERLIN: NATURE PORTFOLIO. ISSN 1759-507X

Full text not available from this repository.

Abstract

New data from the ILLUMINATE-A trial of lumasiran demonstrate the safety and efficacy of this RNA interference therapeutic in patients with primary hyperoxaluria type 1. Further studies are required to investigate the potential long-term benefits of this promising therapy.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Erger, Florian UNSPECIFIED orcid.org/0000-0002-2768-1702 UNSPECIFIED Beck, Bodo B. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-567318
DOI:	10.1038/s41581-021-00449-9
Journal or Publication Title:	Nat. Rev. Nephrol.
Volume:	17
Number:	9
Page Range:	S. 573 - 575
Date:	2021
Publisher:	NATURE PORTFOLIO
Place of Publication:	BERLIN
ISSN:	1759-507X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ALANINE; MUTATION Multiple languages Urology & Nephrology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/56731